Holen Sie sich die Stockscreener-App
32.14
3.28%
-1.09
Handel nachbörslich:
31.52
-0.62
-1.93%
Schlusskurs vom Vortag:
$33.23
Offen:
$32.73
24-Stunden-Volumen:
602.75K
Relative Volume:
0.60
Marktkapitalisierung:
$2.52B
Einnahmen:
$1.55M
Nettoeinkommen (Verlust:
$-258.76M
KGV:
-8.251
EPS:
-3.8953
Netto-Cashflow:
$-213.66M
1W Leistung:
-6.05%
1M Leistung:
+6.07%
6M Leistung:
+23.66%
1J Leistung:
+53.56%
1-Tages-Spanne:
$31.65
$33.04
1-Wochen-Bereich:
$31.65
$34.96
52-Wochen-Spanne:
$17.85
$35.79
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
32.14 | 2.61B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.43 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Hochstufung | Barclays | Underweight → Overweight |
| 2026-03-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Underweight |
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com
[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan
Celldex (NASDAQ: CLDX) sets 2026 virtual meeting, seeks approval for equity plan - Stock Titan
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics announces public offering of common stock - MSN
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Yahoo Finance
Is Celldex (CLDX) stock a strategic buy | Q4 2025: EPS Misses ViewsCommunity Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Celldex (CLDX) Operational Review | Q4 2025: Earnings UnderperformPrice Target - Cổng thông tin điện tử tỉnh Lào Cai
Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains - simplywall.st
Why Celldex Stock Is Suddenly Sliding Again - TipRanks
Celldex Therapeutics Inc (CLDX) - MSN
Barclays upgrades Celldex Therapeutics (CLDX) - MSN
Celldex (CLDX) Stock VWAP Analysis (-0.49%) 2026-04-20AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24 - marketscreener.com
Barclays upgrades Celldex stock rating on trial enrollment progress By Investing.com - Investing.com Australia
Barclays upgrades Celldex stock rating on trial enrollment progress - Investing.com UK
Celldex (CLDX) Stock: Performance Drivers (Modest Uptick) 2026-04-18Real Trader Network - Cổng thông tin điện tử tỉnh Lào Cai
Celldex Therapeutics stock hits 52-week high at 34.55 USD By Investing.com - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighHere's What Happened - MarketBeat
Celldex Therapeutics stock hits 52-week high at 34.55 USD - Investing.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - MarketBeat
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex Therapeutics Raises $345 Million in Public Offering of Common Stock - Global Legal Chronicle
A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data - Sahm
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - Stock Traders Daily
What do ownership trends show for Celldex (CLDX) Stock | Price at $31.79, Up 1.39%Theta Decay - Cổng thông tin điện tử Tỉnh Sơn La
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Celldex Therapeutics Closes $345M Public Stock Offering - National Today
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Celldex Therapeutics Inc-Aktie (CLDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
1.40%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):